Inovio Pharmaceuticals opened lower at $1.44, compared with its previous close of $1.48. In the last trading session, the stock traded between $1.33 and $1.53. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Inovio Pharmaceuticals is now worth
$ 1.69
Resulting in a loss of
$ 98.31 (98.31%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.01 (-0.68%)
Day High
$1.53
Day Low
$1.33
Day Open
$1.44
Prev Close
$1.48
Volume
76,18,840
1W Return
-9.29%
1M Return
32.58%
3M Return
91.75%
6M Return
2.45%
1Y Return
-26.75%
Market Cap ($ Mn)
274
PE Ratio
-
PB Ratio
24.30
PEG Ratio
-
ROE
-257.94%
ROCE
-213.55%
EPS (TTM)
$-0.45
1 Week
-9.29%
1 Month
32.58%
3 Months
91.75%
6 Months
2.45%
9 Months
-9.01%
HC Wainwright reiterates Buy on Inovio, holds $5 target
HC Wainwright & Co. reiterated a Buy rating on Inovio Pharmaceuticals. The firm maintained its $5 price target for the stock. Analyst Raghuram Selvaraju issued the rating update.
TodayPiper Sandler reiterates Overweight on Inovio, cuts price target to $6
Piper Sandler reiterated an Overweight rating on Inovio Pharmaceuticals. The price target was lowered from $8 to $6. Analyst Edward Tenthoff maintained the bullish stance despite the cut.
YesterdayINOVIO to present at Jefferies and Piper Sandler healthcare conferences
INOVIO will present at the Jefferies Global Healthcare Conference in London on November 18, 2026. Management will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference in New York on December 1, 2026. One-on-one meetings with investors are scheduled during both events. Presentation replays will be available for 90 days after each conference.
YesterdayJefferies maintains Buy on Inovio Pharmaceuticals, lifts price target to $8
Jefferies maintains a Buy rating on Inovio Pharmaceuticals. Price target raised from $3 to $8 by analyst Roger Song. The upgrade reflects a revised valuation outlook for the company.
6 days agoINOVIO prices $75 million public offering at $1.05 per share
INOVIO Pharmaceuticals priced an underwritten public offering generating approximately $75 million in gross proceeds. The deal includes 58,747,235 common shares at $1.05 per share and pre-funded warrants for 12,681,337 shares at $1.049. Jefferies and Piper Sandler serve as joint book-running managers, with H.C. Wainwright & Co. as lead manager. The transaction is expected to close on or about November 9, 2026, subject to customary closing conditions.
7 days agoInovio Pharmaceuticals shares jump 192.07% on FDA approval for Voceryq
Inovio Pharmaceuticals shares rose 192.07% to $1.75 following FDA approval. Voceryq is the first plasmid DNA-based immunotherapy approved for RRP. Seven out of 26 patients in the efficacy population showed complete response. Confirmatory study protocol submission required by end of 2026.
10 days ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Inovio Pharmaceuticals is now worth
$ 1.69
Resulting in a loss of
$ 98.31 (98.31%)
Note: Past profits do not guarantee future returns.
